Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The utility of ctDNA in colorectal cancer with peritoneal metastases.

ANZ journal of surgery - 1 Mar 2023

Xue Jessica, Prabhakaran Swetha, Prabhakaran Sowmya, Lim Wei Mou, Guerra Glen, Heriot Alexander, Kong Joseph Cherng

Abstract excerpt

BACKGROUND: The development of peritoneal metastases (PM) in patients with colorectal cancer (CRC) connotates a poor prognosis. Circulating tumour (ctDNA) is a promising tumour biomarker in the management CRC. This systematic review aimed to summarize the role of ctDNA in patients with CRC and PM. METHODS: Following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, a...

Topics

Join the communities discussing this publication.

Biomarkers, Tumor
Colorectal Neoplasms
Mutation
Peritoneal Neoplasms
Prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36200726
DOI: 10.1111/ans.18078

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The utility of ctDNA in colorectal cancer with peritoneal metastases.PMID 36200726Read ↗

Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival.Semantic proximity Read ↗

Discovery of circulating cell-free DNA 5hmC biomarkers for peritoneal metastasis in colorectal and appendiceal cancerSemantic proximity Read ↗

Clinical utility of longitudinal circulating tumor DNA analysis in metastatic colorectal cancer patients receiving palliative chemotherapy.Semantic proximity Read ↗

Peritoneal cell-free DNA as a sensitive biomarker for detection of peritoneal metastasis in colorectal cancer: a prospective diagnostic study: A prospective diagnostic study.Semantic proximity Read ↗

Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer.Semantic proximity Read ↗

Circulating tumor DNA in colorectal cancer: biology, methods and applicationsSemantic proximity Read ↗

Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.Semantic proximity Read ↗

Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid.Semantic proximity Read ↗

Methylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis, prognosis, and predictionSemantic proximity Read ↗

The transition from primary colorectal cancer to isolated peritoneal malignancy is associated with an increased tumour mutational burden.Semantic proximity Read ↗

Longitudinal Comparative Analysis of Circulating Tumor DNA and Matched Tumor Tissue DNA in Patients with Metastatic Colorectal Cancer Receiving Palliative First-Line Systemic Anti-Cancer Therapy.Semantic proximity Read ↗

Plasma ctDNA enhances the tissue-based detection of oncodriver mutations in colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.